Fleury e Bradsaúde criam rede de clínicas oncológicas

Fleury and Atlântica Hospitais, which are both controlled by Bradsaúde, have formed a new company called FleuryOnco that specializes in outpatient oncological treatment. The company will have 50.01% of the capital owned by Fleury and the remaining 49.99% owned by Bradsaúde. Together, the two companies will invest R$ 72 million to open seven oncological clinics in São Paulo and Rio de Janeiro between December of this year and the end of 2027.

FleuryOnco will operate under two brands: Fleury Oncology, which has two premium clinics in São Paulo, and OncoOne, which has five clinics for premium and intermediate (middle-class and upper-middle-class) segments in both cities. Fleury and Atlântica already have a joint venture called Croma Oncology, which was launched in 2024 alongside Beneficência Portuguesa.

Earlier this year, Fleury considered creating an oncology company in partnership with Porto and Oncoclínicas, but abandoned the deal in April due to a lack of time for due diligence, according to CEO Jeane Tsutsui. "The market is large and the trend is growth linked to an aging population and other risk factors. There is space for a new company," Tsutsui told Brazil Journal.

Estimates from both companies indicate that revenues from cancer treatments in Brazil are expected to reach R$ 60 billion this year, and outpatient services account for about 70% of that total. FleuryOnco will focus on the outpatient segment with consultations, diagnostics, medication infusions, treatments like chemotherapy and immunotherapy, and services from professionals such as nutritionists and psychologists.

The new clinics will serve Bradsaúde's clients, but not exclusively: negotiations with other health plans will be conducted, according to Fleury's CEO. Tsutsui and Carlos Marinelli, CEO of Bradsaúde, believe that integrating diagnosis and treatment increases the chances of recovery and improves patients' quality of life, as well as improving the financial sustainability of the companies.

"Scale is also crucial, as it allows us to be more competitive, for example, in medication procurement," Marinelli told Brazil Journal. There is no expectation of revenue for the new company, as the results will be consolidated in Fleury's balance sheet. Currently, services not related to diagnostics, such as orthopedics and ophthalmology, account for about 8% of Fleury's revenue, but this percentage was around 10% before the purchase of Hermes Pardini in 2023.

"Our core is the diagnostics sector, where we have grown organically and inorganically. But we are always looking for growth avenues, such as the oncology segment," Tsutsui said. Both companies have Bradesco as a shareholder: the bank controls Bradsaúde and holds 25% of Fleury's capital.